user

Real World Treatment of Patients with Relapsed/Refractory Myeloma

被引：1
|
作者：
Dimopoulos, Meletios A. [1 ]
Ntanasis-Stathopoulos, Ioannis [1 ]
Terpos, Evangelos [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Plasma Cell Dyscrasias Unit, 80 Vas Sofias Ave, Athens 11528, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷
关键词：
MM; multiple myeloma; real-world; refractory; relapsed; MULTIPLE-MYELOMA; DEXAMETHASONE; EFFICACY; POMALIDOMIDE; LENALIDOMIDE; MULTICENTER; SURVIVAL; THERAPY; CARE;
D O I：
10.1016/j.clml.2019.07.405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EXABS-MM-4
引用
收藏
页码：S24 / S27
页数：4
相关论文
共 50 条
  • [31] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    [J]. FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [32] Selinexor for the treatment of patients with relapsed or refractory multiple myeloma
    Babar, Anum
    Babar, Maham
    Zubair, Hina
    Shahid, Arzu
    Rafique, Sana
    Bano, Maimona
    Waleed, Madeeha Subhan
    Khan, Maimoona
    Inayat, Arslan
    Safi, Danish
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 535 - 546
  • [33] TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Ioana, I.
    Liviu, C.
    Maria, C.
    Claudiu, I.
    Maria, I.
    Mihai, I.
    Dacian, O.
    Ovidiu, P.
    Cristina, S.
    Despina, C.
    Hortensia, I.
    [J]. HAEMATOLOGICA, 2013, 98 : 614 - 614
  • [34] A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
    Rios-Tamayo, Rafael
    Soler, Juan Alfons
    Garcia-Sanchez, Ricarda
    Persona, Ernesto Perez
    Arnao, Mario
    Garcia-Guinon, Antoni
    Domingo, Abel
    Gonzalez-Pardo, Miriam
    de la Rubia, Javier
    Mateos, Maria Victoria
    [J]. HEMATOLOGY, 2023, 28 (01)
  • [35] Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma With Daratumumab: A Systematic Literature Review
    Gros Otero, B.
    Gungor, G.
    Gruppe, T. L.
    Wan, M.
    Jenkins, C.
    Helme, K.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S494 - S494
  • [36] REAL-WORLD CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN US PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
    Nicacio, L. Viana
    Calkins, G.
    Curtis, M.
    Kohansimeh, J.
    Lindberg, F. P.
    Larrabee, K.
    Jaskiw, A.
    Feinstein, R. N.
    Terry, M.
    Plotkin, L.
    Palladino, M. L.
    Krishna, A.
    Green, R. J.
    [J]. HAEMATOLOGICA, 2015, 100 : 742 - 742
  • [37] Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/Refractory Multiple Myeloma (rrMM) Patients
    Shao, Changxia
    Monberg, Matthew
    Cao, Xiting
    Zhou, Wei
    Zhong, Yichen
    Marinello, Patricia
    [J]. BLOOD, 2016, 128 (22)
  • [38] Real-World Treatment Patterns of Patients Initiating Third-Line Therapy in Relapsed or Refractory Multiple Myeloma in Europe
    Lehne, Moritz
    Kortuem, K. Martin
    Zamagni, Elena
    d'Estrube, Tim
    Shukla, Soham
    Zhuleku, Evi
    Ghiani, Marco
    Hanna, Maya
    Maywald, Ulf
    Wilke, Thomas
    Perera, Sue
    [J]. BLOOD, 2022, 140 : 12485 - 12486
  • [39] Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab
    Richter, Joshua
    Anupindi, Vamshi Ruthwik
    Yeaw, Jason
    Kudaravalli, Suneel
    Zavisic, Stojan
    Shah, Drishti
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 395 - 409
  • [40] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    [J]. HAEMATOLOGICA, 2016, 101 : 538 - 539
12345